عرض بسيط للتسجيلة

المؤلفGorachinov, Filip
المؤلفMraiche, Fatima
المؤلفMoustafa, Diala Alhaj
المؤلفHishari, Ola
المؤلفIsmail, Yomna
المؤلفJoseph, Jensa
المؤلفCrcarevska, Maja Simonoska
المؤلفDodov, Marija Glavas
المؤلفGeskovski, Nikola
المؤلفGoracinova, Katerina
تاريخ الإتاحة2023-05-04T05:56:23Z
تاريخ النشر2023-02-22
اسم المنشورBeilstein Journal of Nanotechnology
المعرّفhttp://dx.doi.org/10.3762/bjnano.14.23
الاقتباسGorachinov, F., Mraiche, F., Moustafa, D. A., Hishari, O., Ismail, Y., Joseph, J., ... & Goracinova, K. (2023). Nanotechnology–a robust tool for fighting the challenges of drug resistance in non-small cell lung cancer. Beilstein Journal of Nanotechnology, 14(1), 240-261.
الرقم المعياري الدولي للكتاب2190-4286
معرّف المصادر الموحدhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85150911005&origin=inward
معرّف المصادر الموحدhttp://hdl.handle.net/10576/42315
الملخصGenomic and proteomic mutation analysis is the standard of care for selecting candidates for therapies with tyrosine kinase inhibitors against the human epidermal growth factor receptor (EGFR TKI therapies) and further monitoring cancer treatment efficacy and cancer development. Acquired resistance due to various genetic aberrations is an unavoidable problem during EGFR TKI therapy, leading to the rapid exhaustion of standard molecularly targeted therapeutic options against mutant variants. Attacking multiple molecular targets within one or several signaling pathways by co-delivery of multiple agents is a viable strategy for overcoming and preventing resistance to EGFR TKIs. However, because of the difference in pharmacokinetics among agents, combined therapies may not effectively reach their targets. The obstacles regarding the simultaneous co-delivery of therapeutic agents at the site of action can be overcome using nanomedicine as a platform and nanotools as delivery agents. Precision oncology research to identify targetable biomarkers and optimize tumor homing agents, hand in hand with designing multifunctional and multistage nanocarriers that respond to the inherent heterogeneity of the tumors, may resolve the challenges of inadequate tumor localization, improve intracellular internalization, and bring advantages over conventional nanocarriers
اللغةen
الناشرBeilstein-Institut Zur Forderung der Chemischen Wissenschaften
الموضوعco-delivery nanoparticles
combinatorial therapy
EGFR TKI resistance
non-small cell lung cancer (NSCLC)
overcoming and preventing resistance
العنوانNanotechnology – a robust tool for fighting the challenges of drug resistance in non-small cell lung cancer
النوعArticle
الصفحات240-261
رقم المجلد14
dc.accessType Open Access


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة